See more : Asia Broadband, Inc. (AABB) Income Statement Analysis – Financial Results
Complete financial analysis of Puma Biotechnology, Inc. (PBYI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Puma Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- iStar Inc. (STAR-PI) Income Statement Analysis – Financial Results
- Alliance Integrated Metaliks Limited (AIML.BO) Income Statement Analysis – Financial Results
- PhoneX Holdings, Inc. (PXHI) Income Statement Analysis – Financial Results
- Antisense Therapeutics Limited (ANP.AX) Income Statement Analysis – Financial Results
- Riber S.A. (ALRIB.PA) Income Statement Analysis – Financial Results
Puma Biotechnology, Inc. (PBYI)
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 235.64M | 228.00M | 253.20M | 225.10M | 272.30M | 251.00M | 27.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -281.10K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 62.68M | 55.10M | 63.70M | 39.40M | 36.80M | 34.60M | 5.60M | 1.15M | 776.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 172.96M | 172.90M | 189.50M | 185.70M | 235.50M | 216.40M | 22.10M | -1.15M | -776.00K | 0.00 | 0.00 | 0.00 | -281.10K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 73.40% | 75.83% | 74.84% | 82.50% | 86.49% | 86.22% | 79.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 50.38M | 52.20M | 71.90M | 97.70M | 132.90M | 164.90M | 207.80M | 222.80M | 208.50M | 122.90M | 45.05M | 49.60M | 826.37K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 88.43M | 89.98M | 116.29M | 118.49M | 140.51M | 146.19M | 106.70M | 53.80M | 31.80M | 19.40M | 9.79M | 24.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 881.00K | 22.00K | 6.00K | -88.00K | 1.19M | 12.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 89.31M | 90.00M | 116.30M | 118.40M | 141.70M | 146.20M | 106.70M | 53.80M | 31.80M | 19.40M | 9.79M | 24.80M | 9.32M | 15.98K | 16.84K | 14.08K | 0.00 |
| Other Expenses | 625.00K | -28.00K | 300.00K | 400.00K | 200.00K | -9.70M | -100.00K | -400.00K | 25.00K | -14.00K | 2.00K | 293.00K | 10.70K | 0.00 | 0.00 | 0.00 | -15.09M |
| Operating Expenses | 140.32M | 142.20M | 188.20M | 216.10M | 274.60M | 311.10M | 314.50M | 276.60M | 240.30M | 142.30M | 54.83M | 74.40M | 10.16M | 15.98K | 16.84K | 14.08K | -15.09M |
| Cost & Expenses | 203.00M | 197.30M | 251.90M | 255.50M | 311.40M | 345.70M | 320.10M | 276.60M | 240.30M | 142.30M | 54.83M | 74.40M | 10.16M | 15.98K | 16.84K | 14.08K | -15.09M |
| Interest Income | 2.61M | 800.00K | 100.00K | 500.00K | 2.80M | 1.80M | 1.20M | 1.00M | 1.00M | 300.00K | 172.00K | 100.00K | 3.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.33M | 11.50M | 12.80M | 14.10M | 15.00M | 11.00M | 700.00K | 958.00K | 971.00K | 324.00K | 172.00K | 98.00K | 3.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 11.52M | 8.92M | 10.60M | 7.20M | 4.80M | 7.38M | 2.81M | 1.15M | 776.00K | 627.00K | 423.00K | 265.00K | 10.70K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 47.52M | 20.97M | -5.40M | -38.54M | -55.72M | -95.21M | -288.42M | -275.45M | -239.50M | -141.65M | -54.41M | -74.09M | -10.22M | -15.98K | -16.84K | -14.08K | -15.09M |
| EBITDA Ratio | 20.17% | 13.82% | 0.67% | -13.11% | -13.26% | -40.88% | -1,051.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,580.97% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 32.64M | 23.70M | -8.90M | -30.40M | -39.10M | -94.70M | -292.40M | -276.60M | -240.30M | -142.30M | -54.83M | -74.40M | -10.16M | -15.98K | -16.84K | -14.08K | -15.09M |
| Operating Income Ratio | 13.85% | 10.39% | -3.51% | -13.51% | -14.36% | -37.73% | -1,055.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,613.24% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -9.97M | -23.26M | -30.09M | -29.39M | 53.00K | -18.92M | 435.00K | 585.00K | 996.00K | 310.00K | 174.00K | 98.00K | -76.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 22.67M | 500.00K | -28.80M | -59.80M | -75.60M | -113.60M | -292.00M | -276.00M | -239.30M | -142.00M | -54.66M | -74.30M | -10.23M | -15.98K | -16.84K | -14.08K | -15.09M |
| Income Before Tax Ratio | 9.62% | 0.22% | -11.37% | -26.57% | -27.76% | -45.26% | -1,054.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,640.35% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.08M | 500.00K | 300.00K | 200.00K | 7.12M | -7.92M | -2.21M | -2.15M | -1.75M | -941.00K | -172.00K | -267.00K | 76.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 21.59M | 912.00K | -29.10M | -60.00M | -82.72M | -113.60M | -292.00M | -276.00M | -239.30M | -142.00M | -54.66M | -74.30M | -10.23M | -15.98K | -16.84K | -14.08K | -15.09M |
| Net Income Ratio | 9.16% | 0.40% | -11.49% | -26.65% | -30.38% | -45.26% | -1,054.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,640.35% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.46 | 0.02 | -0.72 | -1.52 | -2.13 | -2.99 | -7.86 | -8.29 | -7.45 | -4.73 | -1.90 | -3.42 | -0.51 | 0.00 | -0.01 | 0.00 | -0.38 |
| EPS Diluted | 0.45 | 0.02 | -0.72 | -1.52 | -2.13 | -2.99 | -7.86 | -8.29 | -7.45 | -4.73 | -1.90 | -3.42 | -0.51 | 0.00 | -0.01 | 0.00 | -0.38 |
| Weighted Avg Shares Out | 47.13M | 44.67M | 40.64M | 39.58M | 38.77M | 37.94M | 37.17M | 33.30M | 32.13M | 30.01M | 28.70M | 21.73M | 20.04M | 7.75M | 3.00M | 3.00M | 39.29M |
| Weighted Avg Shares Out (Dil) | 47.55M | 44.93M | 40.64M | 39.58M | 38.77M | 37.94M | 37.17M | 33.30M | 32.13M | 30.01M | 28.70M | 21.73M | 20.04M | 7.75M | 3.00M | 3.00M | 39.29M |
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of an inducement award to a November new hire, as required under Nasdaq Listing Rule 5635(c)(4).
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
Puma Biotechnology starts the phase II ALISCA-Breast1 study on alisertib for treating hormone receptor-positive, HER2-negative metastatic breast cancer.
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up
Puma Biotechnology beats third-quarter 2024 estimates for both the top and the bottom lines. The company updates its 2024 financial guidance.
Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - CEO, President and Chairman Maximo Nougues - CFO Jeff Ludwig - Chief Commercial...
Puma Biotech (PBYI) Q3 Earnings and Revenues Surpass Estimates
Puma Biotech (PBYI) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.17 per share a year ago.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 4, 2024, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 5,625 shares of Puma common...
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Puma Biotechnology, Inc. (NASDAQ: PBYI) and Encourages Investors to Contact the Firm
PHILADELPHIA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Puma Biotechnology, Inc. (“Puma”) (NASDAQ: PBYI) on behalf of the company's shareholders.
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected
Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.
Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2024 Earnings Call August 1, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chief Executive Officer, President and Chairman Maximo Nougues - Chief Financial Officer Jeff...
Source: https://incomestatements.info
Category: Stock Reports